Teva Didn't Infringe OxyContin Patents, NY Judge Rules

Law360, Los Angeles (January 14, 2014, 6:32 PM EST) -- A New York federal judge on Tuesday found that Teva Pharmaceuticals USA Inc. did not infringe any valid Purdue Pharma LP patent when it attempted to sell a generic version of narcotic pain medication OxyContin.

U.S. District Judge Sidney H. Stein concluded that Purdue had failed to prove Teva had infringed U.S. Patent Number 7,776,314 when it sought approval from the U.S. Food and Drug Administration to sell bioequivalents of OxyContin, and that the asserted claims in the remaining four patents-in-suit — U.S. Patent Numbers 7,674,799,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.